NeoGenomics, Inc. (NEO) vs PDS Biotechnology Corporation (PDSB)
A side-by-side comparison of NeoGenomics, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
NEO
NeoGenomics, Inc.
$18.47HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
PDSB
PDS Biotechnology Corporation
$0.75HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — NEO vs PDSB
growth of $100 · dividends reinvested · last 10yNEO +119.0% (+8.2%/yr)PDSB -99.7% (-43.4%/yr)NEO compounded faster over this window
Log scale — wide-divergence pair
NEO PDSB
NEO vs PDSB: by the numbers
- •NEO is the larger company ($475M vs $42M market cap).
- •Both run net losses; PDSB's is the smaller (0.00% vs -6.77% net margin).
Metrics side by side
Valuation
| Metric | NEO | PDSB |
|---|---|---|
| Forward P/E | 101.08 | N/A |
| P/S ratio | 0.62 | N/A |
| P/B ratio | 0.60 | N/A |
Profitability
| Metric | NEO | PDSB |
|---|---|---|
| Gross margin | 42.92% | 0.00% |
| Operating margin | -8.63% | 0.00% |
| Net margin | -6.77% | 0.00% |
| ROE | -6.60% | N/A |
| ROIC | -5.29% | -3699.99% |
Growth (annualized)
| Metric | NEO | PDSB |
|---|---|---|
| Revenue CAGR (5Y) | 9.41% | N/A |
| Total return CAGR (5Y) | -18.18% | -45.19% |
Frequently asked
- How have NEO and PDSB total returns compared?
- Over the past 10 years, NEO delivered 8.10% and PDSB delivered -43.37% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.